Table 2. Rates and risk of surgery, hospitalization, or discontinuation of anti-TNF therapy or surgery in patients receiving anti-TNF combination therapy or monotherapy.
| Infliximab | Adalimumab | Combined Anti-TNF | |||||
|---|---|---|---|---|---|---|---|
| Outcome | Rate in Combination Therapy (E/100 PY) | Rate in Mono-therapy (E/100 PY) | Adjusted HR* (95% CI) | Rate in Combination Therapy (E/100 PY) | Rate in Mono-therapy (E/100 PY) | Adjusted HR* (95% CI) | Adjusted HR* (95% CI) |
| Surgery | |||||||
| With manual review | 6.1 | 3.9 | 1.40 (0.75-2.62) | 4.9 | 6.1 | 0.90 (0.39-2.04) | 1.20 (0.73-1.96) |
| Without manual review | 6.3 | 4.7 | 1.08 (0.60-1.94) | 4.9 | 6.5 | 0.78 (0.35-1.73) | 0.97 (0.60-1.55) |
| Hospitalization | |||||||
| CD as 1° diagnosis | 8.9 | 9.8 | 0.74 (0.46-1.20) | 11.2 | 14.4 | 0.91 (0.52-1.61) | 0.82 (0.57-1.19) |
| CD as 1° or 2° diagnosis | 13.2 | 13.1 | 0.85 (0.56-1.31) | 15.3 | 21.6 | 0.73 (0.45-1.19) | 0.81 (0.59-1.11) |
| CD or UC as 1° or 2° diagnosis | 13.8 | 13.5 | 0.89 (0.58-1.36) | 15.3 | 22.0 | 0.73 (0.45-1.19) | 0.83 (0.60-1.14) |
| Discontinuation or surgery | 53.1 | 55.9 | 1.22 (0.94-1.59) | 51.3 | 70.8 | 0.90 (0.65-1.26) | 1.09 (0.88-1.34) |
| Discontinuation, surgery, or dose escalation | 83.0 | 82.4 | 1.15 (0.83-1.58) | 87.0 | 83.3 | 0.97 (0.58-1.62) | 1.09 (0.83-1.44) |
*
Adjusted for prior immunomodulator use
Abbrevations: E, events; PY, person-years; HR, hazard ratio; CI, confidence interval